TMCnet News
UPDATE - PolarityTE Appoints Paul Mann of Highbridge Capital to Chief Financial OfficerSALT LAKE CITY, June 21, 2018 (GLOBE NEWSWIRE) -- PolarityTE, Inc. (Nasdaq:COOL) today announced that Paul Mann of Highbridge Capital Management is the new Chief Financial Officer of the Company. Mr. Mann has nearly 20 years of financial industry experience, most recently as the Healthcare Portfolio Manager at Highbridge Capital Management. Prior to Highbridge, Mr. Mann held positions with Soros Fund Management, UBS Investment Group, Morgan Stanley and Deutsche Bank. Notably, Mr. Mann began his career as a scientist at Proctor and Gamble and is named as an inventor on patent applications for skincare compounds and technologies. Mr. Mann has an MA (Cantab) and an MEng from Cambridge University where he studied Natural Sciences and Chemical Engineering. He is a CFA charterholder. “Paul is brilliant. From basic science, to healthcare, to corporate strategy, to financial markets—he is simply brilliant,” said Denver M. Lough, MD, PhD, Chairman and Chief Executive Officer of PolarityTE. “This decision to bring Paul onto the Polarity team was easy. His knowledge and experience across the field is phenomenal and his strategic global vision of the market is precisely suited for the Company as we continue to recruit experienced management, clinical and operational talent to further position the Company for growth. We sincerely look forward to an incredible future with him and the new strategic arm, PolarityIS. John Stetson has played a key role in building the company from its inception and we are thrilled to have him serve as Chief Investment Officer and lead PolarityIS, which will focus on driving value through strategic ventures and the monetization of our derivative technologies.” Paul Mann said, “I met the management team of PolarityTE twelve months ago and I have watched the company and technology evolve over that time. It has become increasingly obvious to me that PolarityTE products have the potential to change the future of medical practice and I am very excited to be part of that process. I strongly believe that we are going to improve the clinical outcomes for millions of patients whilst at the same time, generate fantastic returns for our shareholders.” Mr. Mann will be attending the upcoming Key Opinion Leader Summit scheduled for Monday, June 25th at 8:00am ET in New York City. Please RSVP in advance if you plan to attend, as space is limited. To reserve a seat click here. John Stetson, the newly appointed Chief Investment Officer, commented, “I am thrilled to have the opportunity to lead PolarityIS, a new division focused on monetizing PolarityTE’s derivative technologies, developing strategic partnerships, capitalizing on growth acquisitions, and leveraging PolarityTE’s science to create shareholder value. We believe there are significant opportunities for our platform technology and look forward to evaluating many strategic ventures.” About PolarityTE™ About SkinTE™ SkinTE is for autologous use only. Aseptic technique during harvest and deployment of SkinTE is mandatory. SkinTE is regulated by the FDA as an HCT/P solely under Section 361 of the Public Health Service Act and 21 CFR 1271. The FDA has specific regulations governing HCT/Ps. HCT/Ps that meet the criteria for regulation solely under Section 361 of the Public Health Service Act and 21 CFR 1271 (361 HCT/Ps) are not subject to pre-market clearance or approval requirements, but are subject to post-market regulatory requirements. Forward Looking Statements POLARITYTE, the POLARITYTE logo, POLARITYIS, and SKINTE are all trademarks or registered trademarks of PolarityTE, Inc. CONTACT Investors: Hans Vitzthum Media: |